ID   EW-3
AC   CVCL_1216
SY   EW3; IARC-EW3; IARC-EW-3; IARC-EW 3
DR   CLO; CLO_0009872
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1216
DR   Cell_Model_Passport; SIDM00202
DR   ChEMBL-Cells; CHEMBL3308521
DR   ChEMBL-Targets; CHEMBL2366307
DR   Cosmic; 684070
DR   Cosmic; 949161
DR   Cosmic; 1995405
DR   Cosmic; 2250460
DR   Cosmic-CLP; 949161
DR   DepMap; ACH-002118
DR   EGA; EGAS00001000978
DR   GDSC; 949161
DR   GEO; GSM510005
DR   GEO; GSM1669789
DR   IARC_TP53; 27038
DR   IARC_TP53; 27169
DR   LINCS_LDP; LCL-1452
DR   PharmacoDB; EW3_358_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1216
DR   PubChem_Cell_line; CVCL_1216
DR   Wikidata; Q54833002
RX   DOI=10.5282/edoc.27750;
RX   PubMed=6713356;
RX   PubMed=11423975;
RX   PubMed=16631476;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=21822310;
RX   PubMed=25223734;
RX   PubMed=26428435;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=11423975; PubMed=16631476).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Arg216Ter (c.646C>T); Zygosity=Unspecified (PubMed=25223734).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.852_858del7; Zygosity=Unspecified (PubMed=19787792; PubMed=26428435).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.33%; East Asian, North=0.83%; East Asian, South=0.4%; South Asian=6.18%; European, North=47.05%; European, South=45.2% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; PubMed=19787792
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 16,18
ST   D19S433: 13,15
ST   D21S11: 29,31.2
ST   D2S1338: 20,22
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,11
ST   D8S1179: 12,14
ST   FGA: 22,25
ST   SE33: 15.3,16
ST   TH01: 9.3,10
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=6713356; DOI=10.1016/0165-4608(84)90002-5;
RA   Turc-Carel C., Philip I., Berger M.-P., Philip T., Lenoir G.M.;
RT   "Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a
RT   reciprocal translocation t(11;22)(q24;q12).";
RL   Cancer Genet. Cytogenet. 12:1-19(1984).
//
RX   PubMed=11423975; DOI=10.1038/sj.onc.1204437;
RA   Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V.,
RA   Weissman B.E., Delattre O.;
RT   "Analysis of the expression of cell cycle regulators in Ewing cell
RT   lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.";
RL   Oncogene 20:3258-3265(2001).
//
RX   PubMed=16631476; DOI=10.1016/j.cancergencyto.2005.11.006;
RA   Szuhai K., IJszenga M., Tanke H.J., Rosenberg C., Hogendoorn P.C.W.;
RT   "Molecular cytogenetic characterization of four previously established
RT   and two newly established Ewing sarcoma cell lines.";
RL   Cancer Genet. Cytogenet. 166:173-179(2006).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//